Clinical Trials Logo

Hematologic Neoplasms clinical trials

View clinical trials related to Hematologic Neoplasms.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT05860075 Terminated - Clinical trials for Hematologic Malignancy

Exploratory Study of IMM01 for Injection in the Treatment of Refractory or Recurrent Hematologic Malignancy

Start date: November 19, 2019
Phase: Phase 1
Study type: Interventional

This is a multi-center, open-label, dose-escalation and cohort-expansion phase I clinical study to evaluate the safety and tolerability, pharmacokinetics profile, efficacy and immunogenicity of IMM01 in subjects with refractory or recurrent hematologic malignancy.

NCT ID: NCT04865419 Terminated - Clinical trials for Haematological Malignancies

Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies

Start date: June 11, 2021
Phase: Phase 1
Study type: Interventional

The purpose of the study is to the evaluate safety, tolerability, pharmacokinetics (PK), and efficacy of AZD0466 as monotherapy in partciapants with advanced haematological malignancies and also to assess drug-drug interaction (DDI) potential between AZD0466 and the azole antifungal voriconazole.

NCT ID: NCT04631211 Terminated - Clinical trials for Myelodysplastic Syndromes

Thrombosomes® in Bleeding Thrombocytopenic Patients Study

Start date: March 5, 2021
Phase: Phase 2
Study type: Interventional

This prospective, multicenter, randomized, open-label, Phase 2, parallel, dose ranging, multidose trial will enroll patients into 3 Thrombosomes dose groups and 1 control liquid stored platelets (LSP) group in order to evaluate, in a dose-escalation manner, the safety, and impact on bleeding, and the preliminary effect on coagulation measures of increasing doses of allogeneic Thrombosomes in comparison to standard of care, LSP.

NCT ID: NCT04504708 Terminated - Clinical trials for Chronic Lymphocytic Leukemia

Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies

Start date: February 17, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

ZX-101A-101 is a Phase 1/2a, first-in-human, open-label, multicenter, multiple-ascending dose study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamic, and preliminary antitumor activity of ZX-101A administered orally (PO) once daily (QD) in 28-day cycles in patients with relapsed/resistant or refractory advanced hematologic malignancies [Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), indolent NHL, and other NHL subtypes).

NCT ID: NCT04473937 Terminated - Clinical trials for Hematologic Malignancy

Radiation Post-CAR T in Refractory Lymphoma

Start date: January 5, 2021
Phase: N/A
Study type: Interventional

This study is evaluating the safety and efficacy of using radiotherapy in participants who have refractory lymphoma shortly after receiving CAR T cell therapy (axicel or tisacel).

NCT ID: NCT04347226 Terminated - Solid Tumor Clinical Trials

Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19

Start date: April 16, 2020
Phase: Phase 2
Study type: Interventional

This study is for patients that are hospitalized for Coronavirus Disease 2019 (COVID-19). The purpose of this study is to see whether neutralizing interleukin-8 (IL-8) with BMS-986253 can help improve the health condition of participants infected with COVID-19. This is the first in-human study of this investigational product specifically in patients with severe COVID-19. Currently there are no FDA approved medications that improve the chance of survival in patients diagnosed with COVID-19. However there are usual treatments currently being used to help treat COVID-19 patients and BMS-986253 will be compared to these standard of care treatments in this study.

NCT ID: NCT04214093 Terminated - Multiple Myeloma Clinical Trials

A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors

Start date: December 16, 2019
Phase: Phase 1
Study type: Interventional

This is a first-time-in-human (FTIH), Phase 1 study to determine the safety, tolerability, maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and pharmacokinetics (PK) of AZD0466 in patients with solid tumors, lymphoma and multiple myeloma at low risk for tumor lysis syndrome (TLS), as well as in patients at intermediate risk or high risk of TLS with hematologic malignancies for whom no standard therapy exists. Once an MTD/RP2D has been determined in the dose escalation portion, further disease-specific expansions (solid tumor and hematologic) will be undertaken. Combinations of AZD0466 with other standard of care treatments may be evaluated in the future.

NCT ID: NCT04093622 Terminated - Clinical trials for Hematological Malignancy

Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy

Start date: October 4, 2019
Phase:
Study type: Observational

The purpose of the study is to assess long-term side effects from subjects who receive a Fate Therapeutics genetically modified NK cell product. Subjects who previously took part in a Fate Therapeutics study and received genetically changed NK cells will take part in this long-term follow-up study. Subjects will join this study once they complete the parent interventional study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study. For a period of 15 years starting from the last administration of Fate Therapeutics genetically modified NK cell product, subjects will be assessed for long-term safety and survival through questionnaires and blood tests.

NCT ID: NCT03978312 Terminated - Cancer Clinical Trials

Nutrition Health Literacy of Cancer Patients and Their Support Networks.

NiiCproject
Start date: September 1, 2019
Phase:
Study type: Observational

An exploration of the impact of nutrition literacy on ability of cancer patients and their support networks to get, understand and use nutrition information during cancer treatment.

NCT ID: NCT03963024 Terminated - Multiple Myeloma Clinical Trials

Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT

TrRaMM-TMI
Start date: February 12, 2014
Phase: Phase 1
Study type: Interventional

TrRaMM-TMI is a phase I trial to evaluate the feasibility and efficacy of an original sequential TMI/TrRaMM (Total Marrow Irradiation/Treosulfan-Rapamycin-Mycophenolate Mofetil) schedule in patients with hematological malignancies in advanced stage of disease undergoing an allogenic Stem Cell Transplant (SCT). The aim is to determine the maximum tolerated dose of TMI when combined with conditioning chemotherapy to transplant according to TrRaMM schedule.